In 2017, meta-analysis of 580 cancer cases among 34,569 participants from 46 short-term randomized controlled trials (RCTs) indicated that treatment with SGLT2 inhibitors was not significantly associated with an increased risk of overall cancer. The gene discussed is SLC5A2; the disease is cancer.